Form 4: Thermo Fisher COO Exercises Options, Sells Shares

Thermo Fisher Scientific's Executive Vice President & COO, Michel Lagarde, exercised stock options and subsequently sold a portion of the acquired shares.

Summary

• Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific Inc. (TMO), engaged in transactions on December 4, 2025.
• Lagarde exercised stock options to acquire 18,637 shares of common stock at an exercise price of $105.17 per share.
• Lagarde also exercised stock options to acquire 22,046 shares of common stock at an exercise price of $132.66 per share.
• Following the option exercises, Lagarde sold 22,046 shares of common stock at a weighted average price of $563.56 per share.
• The sale transactions occurred at prices ranging from $563.38 to $564.20 per share.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• After these reported transactions, Lagarde directly beneficially owns 84,116.909 shares of common stock.
• The derivative securities (stock options) involved in these exercises now have a beneficial ownership of 0.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there is an insider sale, it's part of a pre-arranged 10b5-1 plan and follows the exercise of options at significantly lower prices, indicating the executive is realizing gains from long-term equity compensation. This is a routine event for executives and not indicative of negative company performance.

Positives

• An executive exercised a significant number of stock options, indicating a realization of value from the company's equity.
• The sale price of $563.56 per share is substantially higher than the exercise prices of $105.17 and $132.66, reflecting significant appreciation in Thermo Fisher Scientific's stock value.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-planned and non-discretionary sale for diversification or liquidity rather than a reaction to new negative information.

Negatives

• An insider sold 22,046 shares of common stock, which could be perceived as a reduction in direct exposure to the company's equity.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports routine insider transactions and does not provide specific information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The exercise of options and subsequent sale by an executive is a routine event for liquidity and diversification, typically having a minor impact on shareholder sentiment. The 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The Form 4 details routine insider transactions involving the exercise of stock options and subsequent sale of a portion of the acquired shares, likely for diversification or liquidity purposes under a pre-arranged 10b5-1 plan. These transactions do not provide new fundamental information about Thermo Fisher Scientific's operational performance or strategic direction that would warrant a change in investment recommendation.

Keywords

Thermo Fisher Scientific, TMO, insider transaction, Form 4, stock options, executive compensation, Rule 10b5-1